Indexat a

Llicència i ús

Citacions

Cited 32 times in

Cited 41 times in

Cited 29 times in

Cited 61 times in

Altmetrics

Grant support

We thank Maria Calvo, Elisenda Coll and Anna Bosch for outstanding technical support in the Confocal microscopy unit (CCiT-UB) and Maria C Carmona for advice on design of small RNA and oligonucleotidc molecules. This work was supported by grants from CDTI-Spanish Ministry of Science and Innovation-DENDRIA contribution, 'nLife all rights reserved' (to AB and FA); Institute de Salud Carlos III PI10/00290 and PI13/01390 (to AB), PI/10/0123 (to JCL) and Centro de Investigation Biomedica en Red de Salud Mental (CIBERSAM); NARSAD Independent Investigator Grant from the Brain & Behavior Research Foundation Grant 20003 (to AB); Ministry of Economy and Competitiveness SAF2012-35183 (to FA) and SAF2011-25020 (to AP); and Generalitat de Catalunya, Secretaria d'Universitat i Recerca del Departament &Economia i Coneixement (SGR2014) Catalan Government Grant 2009SGR220 (to FA). Some of these grants are co-financed by the European Regional Development Fund 'A way to build Europe'. AF-C is a recipient of a fellowship from Spanish Ministry of Education, Culture and Sport.

Anàlisi d'autories institucional

Compartir

Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

Publicat a:Molecular Psychiatry. 21 (3): 328-338 - 2016-03-01 21(3), DOI: 10.1038/mp.2015.80

Autors: Ferres-Coy, A; Galofre, M; Pilar-Cuellar, F; Vidal, R; Paz, V; Ruiz-Bronchal, E; Campa, L; Pazos, A; Caso, J R; Leza, J C; Alvarado, G; Montefeltro, A; Valdizan, E M; Artigas, F; Bortolozzi, A

Afiliacions

Resum

Major depression brings about a heavy socio-economic burden worldwide due to its high prevalence and the low efficacy of antidepressant drugs, mostly inhibiting the serotonin transporter (SERT). As a result, ~80% of patients show recurrent or chronic depression, resulting in a poor quality of life and increased suicide risk. RNA interference (RNAi) strategies have been preliminarily used to evoke antidepressant-like responses in experimental animals. However, the main limitation for the medical use of RNAi is the extreme difficulty to deliver oligonucleotides to selected neurons/systems in the mammalian brain. Here we show that the intranasal administration of a sertraline-conjugated small interfering RNA (C-SERT-siRNA) silenced SERT expression/function and evoked fast antidepressant-like responses in mice. After crossing the permeable olfactory epithelium, the sertraline-conjugated-siRNA was internalized and transported to serotonin cell bodies by deep Rab-7-associated endomembrane vesicles. Seven-day C-SERT-siRNA evoked similar or more marked responses than 28-day fluoxetine treatment. Hence, C-SERT-siRNA (i) downregulated 5-HT1A-autoreceptors and facilitated forebrain serotonin neurotransmission, (ii) accelerated the proliferation of neuronal precursors and (iii) increased hippocampal complexity and plasticity. Further, short-term C-SERT-siRNA reversed depressive-like behaviors in corticosterone-treated mice. The present results show the feasibility of evoking antidepressant-like responses by selectively targeting neuronal populations with appropriate siRNA strategies, opening a way for further translational studies.

Paraules clau